Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques
Name
nihms-1623647.pdf
Description
Accepted version
Size
1.23 MB
Format
Adobe PDF
Checksum (MD5)
3b8506a3c82e8cb324cc8313fb8161e7
Author(s)
Alter, Galit
Yu, Wen-Han
Chandrashekar, Abishek
Borducchi, Erica N.
Ghneim, Khader
Sharma, Ashish
Nedellec, Rebecca
McKenney, Katherine R.
Linde, Caitlyn
Broge, Thomas
Date Issued
October 2020
Journal
Cell
Publisher
Elsevier BV
Citation
Galit Alter et al. "Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques." Cell 183, 1 (October 2020): 185-196.e14. © 2020 Elsevier Inc.
Version
Author's final manuscript
Abstract
Several HIV-1 and SIV vaccine candidates have shown partial protection against viral challenges in rhesus macaques. However, the protective efficacy of vaccine-elicited polyclonal antibodies has not previously been demonstrated in adoptive transfer studies in nonhuman primates. In this study, we show that passive transfer of purified antibodies from vaccinated macaques can protect naive animals against SIVmac251 challenges. We vaccinated 30 rhesus macaques with Ad26-SIV Env/Gag/Pol and SIV Env gp140 protein vaccines and assessed the induction of antibody responses and a putative protective signature. This signature included multiple antibody functions and correlated with upregulation of interferon pathways in vaccinated animals. Adoptive transfer of purified immunoglobulin G (IgG) from the vaccinated animals with the most robust protective signatures provided partial protection against SIVmac251 challenges in naive recipient rhesus macaques. These data demonstrate the protective efficacy of purified vaccine-elicited antiviral antibodies in this model, even in the absence of virus neutralization.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.cell.2020.08.033
